New Delhi, June 16 -- Nifty 50 began today's session higher at 23,924 versus yesterday's close of 23,854. The index is now hovering around 23,910, up nearly 0.25 per cent so far today. The advance/de... Read More
Mumbai, June 16 -- The key equity barometers continued to trade with moderate gains in morning trade, amid US and Iran reached a ceasefire agreement. Softer crude oil prices, easing geopolitical conce... Read More
Singapore, June 16 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Eval... Read More
Singapore, June 16 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and... Read More
Singapore, June 16 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and... Read More
Singapore, June 16 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending ... Read More
Singapore, June 16 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combin... Read More
Singapore, June 16 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the po... Read More
Singapore, June 16 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507... Read More
Singapore, June 16 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemothera... Read More